Cancer and type 2 diabetes are two of the most significant public health burdens facing the world today, and currently available data suggests their prevalence is expected to continue to increase. Nut consumption has long been hypothesized to have a role in preventing both of these diseases, but until now evidence has been inconsistent. A new systematic review and meta-analysis published in Nutrition Reviews on June 16 shows that nut consumption is, indeed, associated with a decreased risk of certain types of cancer, but not type 2 diabetes.
Researchers at the Mayo Clinic in Rochester, Minnesota, and the University of Minnesota in Minneapolis, Minnesota conducted a systematic review and meta-analysis of 36 observational studies (which included 30,708 patients) on the disease-preventive powers of nut consumption to create a comprehensive analysis. Upon completion, the authors concluded: "nut consumption was inversely associated with risk of colorectal cancer, endometrial cancer, and pancreatic cancer, but not with other types of cancer or type 2 diabetes. Overall, nut intake was associated with a decreased risk of cancer."
While many studies have evaluated the disease-preventive powers of nuts, the authors emphasize there is still a scarcity of available data on the relationship between individual types of cancer and nut consumption. Additional studies are consequently needed to more accurately assess these relationships.
"This is the first systematic review and meta-analysis study estimating the association between nut intake and risk of cancers. Our study suggests that nut consumption may be associated with reduced risk of cancers, which may have practical implication. Aligning with the known beneficial effect of nuts on heart diseases, our study may imply that individuals interested in making better food choices to reduce the risk of cancer and heart disease can consider consuming nuts, after considering the caloric and fat contents of different types of nuts", said Lang Wu, the lead author of this study.
This article also discusses:
New blood test detects early lung damage in cancer patients on targeted therapy